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Abstract
Triple negative (ER, PgR and HER2 negative) breast cancers (TNBCs) are often considered as a poor prognostic phenotype.
There is dearth of evidence showing the prevalence and biological behaviour of TNBCs in older women. This study aimed to
analyse their biological characteristics in comparison with a well characterised younger series from a single centre with long
term clinical follow-up. Over 37 years (1973–2010), 1,758 older ($70 years) women with early operable (,5 cm) primary
breast cancer were managed in a dedicated clinic and have complete clinical information available. Of these 813 patients
underwent primary surgery and 575 had good quality tumour samples available for tissue microarray analysis using indirect
immunohistochemistry. A total of 127 patients (22.1%) had TNBCs and full biological analysis of 15 biomarkers was
performed. The results were compared with those of their younger (,70 years) counterparts 342 (18.9%) from a previously
characterised, consecutive series of primary breast cancer treated in the same unit (1986–1998). The 127 older patients with
TNBCs showed lower rates of Ki67 and CK 7/8 positivity and high rates of bcl2 and CK18 positivity when compared with
their younger counterparts (p,0.05). There was no significant difference in the long term clinical outcome between the two
age groups, despite the fact that 47% of the younger patients had adjuvant chemotherapy, while none in the older cohort
received such treatment. EGFR, axillary stage and pathological size showed prognostic significance in older women with
TNBCs on univariate analysis. Despite not having received adjuvant chemotherapy, the older series had clinical outcome
similar to the younger patients almost half of whom had chemotherapy. This appears to be related to other biomarkers (in
addition to ER/PgR/HER2) eg Ki67, bcl2 and cytokeratins which have different expression patterns influencing prognosis.
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Introduction
The risk of breast cancer increases with advancing age. [1].
Oestrogen receptor (ER) positive tumours become more common
in older women [2,3], suggesting a possible change in biology with
age. Many studies have reported an inverse correlation between
ER positivity and Human Epidermal Growth Factor Receptor-2
(HER2) expression [4,5,6,7]. Thus a small proportion of older
women would be expected to have triple negative (ER, proges-
terone (PgR) and HER2 negative) breast cancers (TNBCs).
It is generally believed that TNBCs tend to have a poor
prognosis. Given the lack of conventional therapeutic targets i.e.
hormone receptors and HER2, patients with TNBCs are left with
chemotherapy as the only systemic therapy option, if this is
required as an adjuvant treatment. Conversely, owing to limited
physiological reserve and increased number of co-morbidities,
some older women may not be able to tolerate chemotherapy and
also the Oxford Overview has not yet had sufficient number of
older women from randomised trials to demonstrate a definite and
significant absolute benefit of chemotherapy in this age group [8].
Thus patients and clinicians both show reluctance to use
chemotherapy, and its use in older women still remains debatable.
A lot of research has recently been directed towards TNBCs but
most of the studies are focused on younger patients with minimal
or no representation of older women [9,10], while those focusing
on older women showed inconsistency in defining the age cut-off
for including patients in the older cohort [11] This study aimed to
analyse the biology and clinical outcome of TNBCs in older ($70
years) women and compare the results with their younger
counterparts.
Methods
Over a period of 37 years (1973–2010) 1,758 older ($70 years)
women with early operable primary breast cancer were managed
and followed up in a dedicated clinic, with availability of a
complete set of clinical information from the date of diagnosis till
death or last follow-up. Early operable primary breast cancer was
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defined clinically as tumour size of #5 cm, with no or palpable
mobile ipsilateral axillary lymphadenopathy, without evidence of
distant metastases (cT1-2, N0-1, M0). The patients were initially
identified from the Histopathology archive of paper records
(before 1987, N= 240) and a prospectively established computer-
ised database (since 1987, N= 1,518). The clinical course of the
disease was subsequently confirmed from the clinical notes. The
dedicated clinic, which started off as a surgical clinic, had evolved
into a combined surgical/oncology facility in the recent decade,
following the same clinical guidelines at any time point. Although
there has been a change in the management protocols over the
period as previously described [12], most of the change was
attributed to the use of endocrine therapy as far as systemic
therapy was concerned. Therefore it would be unlikely that the
changes had impacted on patients with TNBCs.
Among all these patients, 813 of them had surgery as their
primary treatment. Of these, 575 had good quality tumour
samples from their surgical specimens available for tissue
microarray (TMA) construction. For the purpose of this study,
the tumour samples were analysed using indirect immunohisto-
chemistry (IHC) on TMAs for ER, PgR, HER2, p53, Cytokeratins
(CK) 5/6, 7/8, 14, 17, 18, 19, Bcl2, E-Cadherin and Muc1.
Assessment of Ki67 was done on whole tumour sections.
Histological grade of the tumours was based on the original
histology report, according to a uniform protocol using the Elston-
Ellis modification of Scarff-Bloom Richardson (SBR) grading
system after 1988 and SBR before 1988 [13].
Younger series
In order to compare with the younger (,70 years) patients,
patients with stage matched (cT1-2,N0-1,M0) TNBCs were
retrieved from a previously characterised institutional database
(Nottingham/Tenovus series) along with the data of the above
mentioned biomarkers [14,15,16]. The Nottingham Tenovus
series consists of clinical and biological data of younger (,70
years) patients with early operable primary breast cancer
established in 1980s and tumours were prospectively analysed
using IHC on TMAs, constructed using surgical specimens
(N= 1809). As it was planned at the outset of the project to
compare the present older series with the younger patients, the
variables collected for the older series were the same as those
collected for the younger patients and the methods for tumour
analyses were the same.
Tissue microarray construction
The TMAs were constructed following the previously described
method [14,17], where the most representative part of the tumour
was identified and a core of 0.6 mm thickness was obtained and
implanted into the TMA block, by using a manual tissue
microarrayer (MP06 Beecher Instruments Inc, USA).
Immunohistochemistry
Indirect IHC was performed using Streptavidin-Biotin Complex
(ABC) method as previously described [14]. Briefly, TMA slides
were incubated at 60u C for 10 minutes, followed by washing with
two Xylene and three alcohol baths for 5 minutes and 10 seconds
each respectively. The slides were treated with citrate buffer for 20
minutes to retrieve the antigen. Endogenous peroxidase activity
was inhibited by 0.3% hydrogen peroxide. The slides were
incubated for a specified time for the primary antibody at room
temperature (details of the antibody dilution and incubation time
are given in Table 1). The secondary antibody was applied for 45
minutes, followed by the treatment with diaminobenzidine and
copper sulphate.
Immunohistochemical scoring
The IHC staining of the biomarkers was assessed by the
percentage of cells stained as well as semi-quantitatively by
McCarty’s histochemical scoring (H-score) [18] method. For intra-
observer reproducibility the cores were scored thrice (by BMS) and
the average of the score was taken as the final score and for inter-
observer concordance an expert pathologist blinded from the
scores and the clinical data, scored 10% of cores. There was high
inter and intra-observer concordance between the scorers (Kappa
score $0.7).
Table 1 summarises the definitions of positivity of different
biomarkers using pre-defined cut-offs.
Statistical methods
Comparison was made between the two age groups ,70 and $
70, using Chi-square test and time dependant variables were
compared using Kaplan-Meier method with application of Log-
rank and generalised Wilcoxon tests as appropriate for statistical
significance. A p-value,0.05 was considered significant. Given the
difference in length of follow-up of the two series, analysis was
carried out according to time periods and comparison was done at
five years from the date of diagnosis to avoid any potential bias.
Breast cancer specific survival measures biological behaviour of
the disease without being influenced by deaths due to causes other
than breast cancer. As the older women are at higher chance of
presenting with a number of co morbidities and a considerable
proportion is life threatening [19], and lead to the higher rate of
non breast cancer deaths [12,20], thus overall survival does not
accurately measure virulence of tumours as it takes all causes of
death into account. Therefore the two groups were compared in
terms of breast cancer specific survival (defined as deaths due to
breast cancer), local recurrence (defined as the re-appearance of
the tumour in the same breast after wide local excision or in the
mastectomy flap), regional recurrence (defined as appearance of
the tumour in ipsilateral axilla) and metastases (defined as distant
recurrence including bone, lung, liver, and also supraclavicular
lymph nodes). Multivariate analysis was carried out using Cox-
regression model. The Predictives Analytic Software (PASW 18,
Chicago, Illinois) was used for data collection and analysis.
Ethical approval
The work presented in this manuscript was part of a study
entitled ‘Development of a molecular genetic classification of
breast cancer’ approved by the Nottingham Research Ethics
Committee (approval number C1080301), who waived the need
for written informed consent from the participants.
Results
Among all age groups 469 patients had TNBCs including 342 in
women,70 years (342 out of 1809, 18.9%) and 127 in older ($70
years) women (127 out of 575, 22.1%). Basic demographic
characteristics of the two age groups are summarised in Table 2.
Older women with TNBCs were significantly of larger patholog-
ical size and lower grade, but there were no significant differences
in histological type and axillary stage.
Biological features
Comparison of the biomarkers between the two age groups
showed that TNBCs in older women had significantly lower
expression of Ki67, more normal p53 and higher expression of
Bcl2 than younger women (Table 2). There was mixed luminal
and basal cytokeratin expression with significantly higher expres-
sion of CK14 and CK18, but a reduction in the expression of
Triple Negative Breast Cancer in Older Women
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CK7/8. There was no difference in the expression of CK17,
CK5/6, CK 19 or Muc1.
Management pattern and clinical outcome
A considerable proportion (47%) of younger (,70 years)
patients received adjuvant chemotherapy as compared to their
older counterparts where none of them received chemotherapy
(Table 2).
At a median follow-up of 46 (longest = 204) months in the older
women and 119 (longest = 135) months in the younger patients,
there was no significant difference in the clinical outcome of the
disease, in terms of recurrence and survival (Table 3, Figure 1).
However there was a trend of even better survival in the older
women (5-years breast cancer specific survival in ,70=73%
versus 79% in older patients), though it did not reach statistical
significance. The 5-year rates of local and regional recurrences in
younger patients were 10% and 9% versus 14% and 14%
respectively in older patients. The rates of metastases were 30%
and 27% in younger and older groups respectively.
The clinical outcome remained similar (ie. no difference) when
comparison was made with stratification according to histological
grade (p-value.0.05) (Data not shown).
Prognostic factors
All the studied biomarkers were analysed for prognostic
significance in the older series. Only EGFR showed prognostic
significance in terms of breast cancer specific survival, along with
stage and pathological size (Figure 2). Patients with EGFR positive
tumours, axillary stage I or II disease, or pathological size ,3 cm
had significantly better breast cancer specific survival. However on
multivariate analysis none of them showed any prognostic
significance.
Discussion
The results of the study show that TNBCs in older women
appear to have less aggressive biology as compared to their
younger counterparts by having more low grade tumours,
reduction of Ki67 expression, more frequent normal p53 and
higher expression of Bcl2. There appears to be no significant
difference in the clinical outcome in the two age groups despite the
fact that a higher proportion of the younger patients received
chemotherapy. Positive EGFR status, lower axillary stage (,4
positive nodes positive) and small pathological size (,3 cm) were
associated with significantly better outcome in older women with
TNBCs, on univariate analysis.
The age cut-offs defining the older population remain
inconsistent across various studies eg 55, 60, 65, 70 or 75 years
have all been used. We defined older population in our study as
women $70 years of age. This age cut-off has been previously
reported to have an association with the beginning of a rapid
decline of physiological reserve [21]. Also this is the same age cut-
off used by our unit when the Nottingham Prognostic Index was
devised and in a few other randomised controlled trials comparing
surgery and primary endocrine therapy in older women [22,23]. It
would therefore appear to be reasonable to use such cut-off for the
ease of comparability.
Overall TNBCs comprise 10–25% of the breast cancer
population regardless of age [9,24,25,26]. There is dearth of
knowledge regarding the pattern of TNBCs with advancing age.
In our study the tumour analysis was carried out using surgical
specimens where there was a natural selection of more ER
negative tumours for primary surgery as those older women with
ER positive tumours who presented with a number of co
morbidities and/or refused to have surgery had an option of
primary endocrine therapy. An audit of a recent consecutive series
of older women (part of this larger series) where the status of ER,
PR and HER2 was determined on needle core biopsies as part of
standard pathology report at the time of their diagnosis showed
13.4% TNBCs [12]. Thus the higher number of TNBCs in older
patients in this study (22.1%) probably reflects the higher ER
negative tumours within the series.
This study has presented comparison of biology and clinical
outcome of this apparently more aggressive phenotype of breast
Table 1. A summary of the anti-bodies source, methods and cut-offs to define positivity of the markers used to analyse biology of
early operable primary breast cancer in older women.
Biomarker Antibody reference Dilution Incubation time Antigen retrieval method Cut –off to define positivity
ER RM-9101-SP1/NeoMarkers 1:100 45 minutes Citrate Buffer 0
PR PgR 636/Dako 1:200 45 minutes Citrate Buffer 0
HER2 Hercep test Kit- Dako Pre-diluted 30 minutes Not required 3+
Ki67 M 7240/Dako 1:100 45 minutes Citrate Buffer 10
P53 DO-7/Novocastra 1:100 45 minutes Citrate Buffer 5
CK5 M26/Thermo Scientific 1:100 45 minutes Citrate Buffer 10
CK5/6 M7237/Dako 1:100 45 minutes Citrate Buffer 10
CK7/8 34779/BioSciences 1:100 45 minutes Citrate Buffer 10
CK14 LL002/Vector Laboratories 1:100 45 minutes Citrate Buffer 10
CK17 E3/Vector Laboratories 1:100 45 minutes Citrate Buffer 10
CK18 M7010/Dako 1:100 45 minutes Citrate Buffer 10
CK19 CM 242A/Biocare Medical 1:100 45 minutes Citrate Buffer 10
Bcl2 M0887/Dako 1:100 45 minutes Citrate Buffer 10
E-Cadherin M3612/Dako 1:100 45 minutes Citrate Buffer 30
Muc1 NCL/Novocastra 1:300 45 minutes Citrate Buffer 20
EGFR 31G7/Zymed 1:30 60 minutes Proteinase K 0
doi:10.1371/journal.pone.0100573.t001
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cancer from a large series in two age groups. Overall there was a
higher rate of grade 3 tumours, high proliferative index, mutant
p53, which is in keeping with the literature [25,26,27]. In this
study, TNBCs in the younger patients showed aggressive biology
with higher rate of grade 3 tumours, Ki67 expression and p53
mutations as seen in many other studies which included younger
patients. However none of these studies compared the two age
groups. There was a mixed picture of luminal (CK7/8 and 18) and
basal (CK 14 and 17) markers. In the older women studied here,
there was a high expression of luminal CK 18, which has never
been reported in the literature and this may have an impact on the
possible better clinical outcome as seen here. However the rate of
CK7/8 positivity was higher in younger patients. The study
showed a high expression of basal markers, in keeping with the
literature [25,27] though it was even higher in older series which
might be due to the higher representation of ER negative tumours
in older women where there is a frequent association with basal
cytokeratins [28,29].
The overall outcome of the two age groups with TNBCs was
poor with a 5-year breast cancer survival of 73% and 79% in ,70
and $70 years age groups respectively, which is in keeping with
the literature [30], as compared to that reported by us (5-year
breast cancer survival being 91% and 90% respectively for the
whole series of older women and in the ER positive subgroup)
[12,20]. However, despite the fact that they did not receive any
adjuvant chemotherapy, the older women did not do any worse
than their younger counterparts. As described above, this could be
explained biologically due to a preponderance of tumours with
lower grade, low proliferation index, normal p53, high Bcl2
proteins and high expression of luminal cytokeratins which all
have been shown to be associated with better clinical outcome.
There is therefore an urgent need of further studies to investigate
this so that clinicians would know how best to select older patients
Table 2. A summary of the general characteristics and biology and management pattern of triple negative breast cancer – young
(,70 years) versus older ($70 years).
Character All N(%) ,70 years $70 years p-value
N(%) N(%)
Median age (range) 57.5 (25.91) 51(25–69) 75(70–91)
Histological types
Ductal carcinoma (no special type) 383(83.3) 276(82.4) 107(85.6) 0.12
Tubular carcinoma 12(2.6) 8(2.4) 4(3.2)
Lobular carcinoma 8(1.7) 3(0.9) 5(4.0)
Other types 57(12.4) 48(14.3) 9(7.2)
Pathological size 0.002
#2 cm 208 (45.4) 169(49.6) 39(33.3)
.2 cm 250(54.6) 172(50.4) 78(66.7)
Axillary lymph node status 0.61
No positive 263(62.2) 213(62.5) 50(61.0)
1–3 positive 111(26.2) 91(26.7) 20(24.4)
$4 positive 49(11.6) 37(10.9) 12(14.6)
Grade 0.007
1 8(1.8) 5(1.5) 3(2.8)
2 45(10.0) 26(7.6) 19(17.4)
3 396(88.2) 309(90.9) 87(79.8)
Ki67 positive 303(75.4) 243(87.7) 60(48.0) ,0.001
p53 positive 242(52.7) 188(55.6) 54(44.6) 0.02
E-Cadherin positive 374(80.6) 284(84.0) 90(71.4) 0.002
Bcl2 positive 149(60.3) 57(43.5) 92(79.3) ,0.001
Muc1 positive 310(75.8) 215(75.2) 95(77.2) 0.37
CK5/6 positive 221(48.0) 160(46.8) 61(51.7) 0.20
CK7/8 positive 436(94.0) 328(95.9) 108(88.5) 0.005
CK14 positive 138(31.2) 97(28.7) 41(39.0) 0.03
CK17 positive 54(23.8) 25(22.5) 29(25.0) 0.38
CK18 positive 297(66.6) 195(60.2) 102(83.6) ,0.001
CK19 positive 401(86.6) 295(86.5) 106(86.9) 0.52
Management pattern
Surgery without adjuvant chemotherapy 296(66.4) 169(53.0) 127(100)
Surgery with adjuvant chemotherapy 150(33.6) 150(47.0) 0
doi:10.1371/journal.pone.0100573.t002
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for adjuvant chemotherapy. This is especially important in those
older patients with poorer physiological reserve and significant co-
morbidities. There could be a valid reason based on tumour biology
for not recommending chemotherapy in some of these patients.
The expression of EGFR showed an association with better
outcome. This has been reported in the literature where others
have demonstrated better outcome of basal like tumours as
compared to pure triple negative/quadruple negative (Quadruple
negatives defined as the tumours negative for ER, PgR, HER2 and
CK5/6 expression) tumours [9]. The risk of dying from breast
cancer in the reported study was 43% higher in the group with
negative CK5/6 and EGFR expression within triple negative
group as compared to the patients who had CK5/6 and EGFR
positive expression [9]. In addition, studies have shown that EGFR
when co-expressed with luminal cytokeratins tends to be associated
with a better prognosis [31]. This might be a possible explanation
of the better outcome associated with EGFR positivity seen in the
present study, where a high expression of CK18 was present in
most cases. The presence of EGFR overexpression is also a
potential good news as anti-EGFR immunotherapy (e.g. cetux-
imab and eroltinib) could be exploited. There is a strong need of
inclusion of older women in clinical trials with anti-EGFR
therapies to assess their clinical effectiveness as well as safety
profile.
Figure 1. Pattern of clinical outcome of triple negative early operable primary breast cancer - Younger (,70 years) versus older ($70 years).
doi:10.1371/journal.pone.0100573.g001
Table 3. A summary of the clinical outcome of triple negative early operable primary breast cancer- younger (,70) versus older ($
70) patients.
Outcome measure 5-year rates in two age groups (%) p-value
,70 years $70 years
Breast cancer specific survival 73 79 0.39
Local recurrence free survival 90 86 0.16
Regional recurrence free survival 91 86 0.40
Metastases free survival 70 73 0.56
doi:10.1371/journal.pone.0100573.t003
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Conclusions
Despite not having received adjuvant chemotherapy, the older
series had clinical outcome similar to the younger patients almost
half of which had chemotherapy. This may be due to other
biomarkers (in addition to ER/PR/HER2) which have different
patterns in these age groups influencing prognosis. The place of
adjuvant chemotherapy in the treatment of these patients has yet
to be identified.
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